Karyopharm’s Selinexor: US FDA Unconvinced By Efficacy In Single-Arm Trial

Oncologic Drugs Advisory Committee will consider whether approval for Karyopharm’s proposed refractory myeloma therapy selinexor should await results from an ongoing Phase III randomized trial.